Data from a Phase 1 trial is the latest bullish news from the biotech that may offer cheap entry to weight-loss mania.
Source: https://www.marketwatch.com/story/vikin ... topstories
Viking Therapeutics posts positive results for oral weight-loss drug. Analysts remain unanimous the stock’s a buy.
